We’ve just created our LinkedIn page. Atticus Pharma, spun out of Zyl? Therapeutics earlier in 2024, now has a CEO (Leigh Hsu PhD/MBA) and a CMO (Dario Paggiarino MD), along with an Executive Chairman (Scott Pancoast) and a CFO (Charles Hinkle), both Harvard Business School alums from the early 80s. Look for exciting posts as Atticus leverages the patented Z-pod? sustained-release delivery system for topicals with novel drugs for lupus lesions and androgenic alopecia.
Atticus Pharma
生物技术研究
Greenville，South Carolina 80 位关注者
Better topical drugs through sustained-release delivery
关于我们
Atticus Pharma has generated a drug pipeline on the strength of an innovative topical drug-delivery platform originally developed at Albert Einstein College of Medicine. The Z-pod? encapsulation technology platform provides sustained release of an API of choice, providing more physiologic dosing and thereby enhancing bioavailability. The technology is highly efficient, scalable, and cost-effective. The lead program is anandamide-loaded Z-pods for the treatment of lupus lesions, an area of high unmet need. The second program is Y200-loaded Z-pods for the treatment of hair loss (androgenic alopecia).
- 网站
-
www.atticuspharma.com
Atticus Pharma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Greenville，South Carolina
- 类型
- 私人持股
- 创立
- 2024
- 领域
- Drug delivery、Sustained release、Deeper penetration into follicles和Enhanced bioavailability
地点
-
主要
获取路线
141 Traction St.
#2093
US，South Carolina，Greenville，29611